523 related articles for article (PubMed ID: 22140653)
1. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Rodrik-Outmezguine VS; Chandarlapaty S; Pagano NC; Poulikakos PI; Scaltriti M; Moskatel E; Baselga J; Guichard S; Rosen N
Cancer Discov; 2011 Aug; 1(3):248-59. PubMed ID: 22140653
[TBL] [Abstract][Full Text] [Related]
2. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
[TBL] [Abstract][Full Text] [Related]
3. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Chandarlapaty S; Sawai A; Scaltriti M; Rodrik-Outmezguine V; Grbovic-Huezo O; Serra V; Majumder PK; Baselga J; Rosen N
Cancer Cell; 2011 Jan; 19(1):58-71. PubMed ID: 21215704
[TBL] [Abstract][Full Text] [Related]
4. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
[TBL] [Abstract][Full Text] [Related]
6. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
[TBL] [Abstract][Full Text] [Related]
7. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
Misra UK; Pizzo SV
J Cell Biochem; 2012 May; 113(5):1488-500. PubMed ID: 22173835
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
10. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
11. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Fan QW; Weiss WA
Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
[TBL] [Abstract][Full Text] [Related]
13. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
14. Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling.
Miyazaki M; McCarthy JJ; Fedele MJ; Esser KA
J Physiol; 2011 Apr; 589(Pt 7):1831-46. PubMed ID: 21300751
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
[TBL] [Abstract][Full Text] [Related]
16. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
17. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax.
Espona-Fiedler M; Soto-Cerrato V; Hosseini A; Lizcano JM; Guallar V; Quesada R; Gao T; Pérez-Tomás R
Biochem Pharmacol; 2012 Feb; 83(4):489-96. PubMed ID: 22155350
[TBL] [Abstract][Full Text] [Related]
18. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
19. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]